Clarius Group LLC Sells 3,228 Shares of Pfizer Inc. (NYSE:PFE)

Clarius Group LLC trimmed its stake in Pfizer Inc. (NYSE:PFE) by 10.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,697 shares of the biopharmaceutical company’s stock after selling 3,228 shares during the quarter. Clarius Group LLC’s holdings in Pfizer were worth $803,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in PFE. Wesbanco Bank Inc. lifted its holdings in shares of Pfizer by 0.9% during the second quarter. Wesbanco Bank Inc. now owns 251,945 shares of the biopharmaceutical company’s stock valued at $7,049,000 after purchasing an additional 2,265 shares in the last quarter. Smith Anglin Financial LLC lifted its holdings in shares of Pfizer by 7.2% during the second quarter. Smith Anglin Financial LLC now owns 22,026 shares of the biopharmaceutical company’s stock valued at $616,000 after purchasing an additional 1,472 shares in the last quarter. Csenge Advisory Group lifted its holdings in shares of Pfizer by 2.9% during the second quarter. Csenge Advisory Group now owns 46,900 shares of the biopharmaceutical company’s stock valued at $1,312,000 after purchasing an additional 1,305 shares in the last quarter. O Keefe Stevens Advisory Inc. lifted its holdings in shares of Pfizer by 104.5% during the second quarter. O Keefe Stevens Advisory Inc. now owns 52,301 shares of the biopharmaceutical company’s stock valued at $1,463,000 after purchasing an additional 26,724 shares in the last quarter. Finally, Advocate Group LLC lifted its holdings in shares of Pfizer by 7.4% during the second quarter. Advocate Group LLC now owns 316,841 shares of the biopharmaceutical company’s stock valued at $8,865,000 after purchasing an additional 21,772 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

PFE traded down $0.19 during midday trading on Friday, reaching $28.57. The company had a trading volume of 4,661,079 shares, compared to its average volume of 39,688,641. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average of $28.80 and a two-hundred day moving average of $27.87. The company has a market cap of $161.89 billion, a P/E ratio of -476.00, a P/E/G ratio of 1.07 and a beta of 0.69. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.19.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.31% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter last year, the business posted $0.67 earnings per share. The firm’s revenue was up 2.1% on a year-over-year basis. As a group, equities research analysts predict that Pfizer Inc. will post 2.68 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.88%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio is currently -2,800.00%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on PFE. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the company from $28.00 to $34.00 in a report on Wednesday. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. UBS Group increased their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Wells Fargo & Company increased their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Morgan Stanley increased their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.